市場調查報告書
商品編碼
1210967
瘙癢症(瘙癢症)藥物的全球市場研究和預測:按藥物類型、疾病類型、分銷渠道和地區分析,2022-2029Global Pruritus Therapeutics Market Size study & Forecast, by Drug Type, by Disease Type, by Distribution Channel and Regional Analysis, 2022-2029 |
2021 年全球瘙癢症治療市場價值約為 79 億美元,預計在 2022-2029 年預測期內將以超過 3.6% 的健康增長率增長。
瘙癢症是皮膚發癢的醫學術語。 許多皮膚瘙癢狀況與皮膚乾燥、過敏和潛在的皮膚狀況有關。 此外,某些形式的皮膚瘙癢症與多種疾病有關,例如癌症、糖尿病、HIV 以及肝膽疾病。 這種情況可以用口服藥物治療。 全球皮膚病患病率的上升、電子藥房增長的出現以及主要市場參與者的戰略舉措是加速市場增長的關鍵因素。
特應性皮炎、過敏性接觸性皮炎和蕁麻疹等皮膚病發病率的增加促進了全球瘙癢症市場的增長。 例如,根據國家生物技術信息中心 (NCBI) 的數據,截至 2019 年,接觸性過敏影響了歐洲約 20% 的總人口。 此外,根據世界過敏組織的數據——截至 2020 年,全球範圍內,接觸性皮炎約佔發達國家所有職業性皮膚病的 85-95%,每年約有 570 萬人次就診。據說 此外,預計新興市場醫療基礎設施的發展和老年人口的增加將為預測期內的市場創造良好的增長前景。 然而,缺乏對潛在疾病的認識阻礙了整個 2022-2029 年預測期內的市場增長。
全球瘙癢症治療市場研究中考慮的主要區域是亞太地區、北美、歐洲、拉丁美洲和世界其他地區。 由於皮膚病的流行和大型製藥公司的存在,北美已成為市場份額的主要地區。 另一方面,由於老年人口增加和製藥行業擴張等因素,預計亞太地區在預測期內將以最高複合年增長率增長。
這項研究的目的是揭示近年來各個細分市場和國家/地區的市場規模,並預測未來幾年的市場規模。 該報告旨在捕捉被調查國家工業的定性和定量方面的情況。
它還提供了關鍵方面的詳細信息,例如決定市場未來增長的驅動因素和挑戰。 此外,它還包含供利益相關者投資的微觀市場潛在機會,以及對主要參與者的競爭格局和產品供應的深入分析。
按藥物類型
皮質類固醇
抗組胺藥
局部麻醉劑
免疫抑製劑
雜項
按疾病
特應性皮炎
過敏性接觸性皮炎
蕁麻疹
雜項
按銷售渠道
醫院藥房
藥店/零售商
在線提供商
Global Pruritus Therapeutics Market is valued at approximately USD 7.9 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 3.6% over the forecast period 2022-2029. Pruritus is a medical term for itchy skin. Most of the itchy skin conditions are associated with Dry skin, allergies, and underlying Skin disease. Moreover, certain types of pruritus are associated with various diseases including cancer, diabetes, HIV, liver & gallbladder diseases among others. This condition can be treated using oral treatments. The increasing prevalence of skin diseases worldwide and growing emergence of e-pharmacy as well as strategic initiatives from leading market players are key factors accelerating the market growth.
The increasing incidences of skin disorders such as Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria are contributing to the growth of the Global Pruritus Market. For instance, according to the National Center for Biotechnology Information (NCBI) - as of 2019, in Europe about 20% of the general population is affected by contact allergies. Moreover, as per World Allergy Organization - as of 2020, globally contact dermatitis accounts for approximately 85 - 95% of all occupational skin diseases in industrialized countries and contributes to an estimated 5.7 million physician visits per year. Also, growing healthcare infrastructure in developing regions and rising number of geriatric individuals would create a lucrative growth prospectus for the market over the forecast period. However, lack of awareness towards underlying disease stifles market growth throughout the forecast period of 2022-2029.
The key regions considered for the Global Pruritus Therapeutics Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading region in terms of market share owing to growing prevalence of skin disorders as well as presence of leading pharmaceutical companies in the region. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as rising geriatric population and rising expansion of pharmaceutical sector in the region.
Major market players included in this report are:
AbbVie Inc.
Amgen Inc.
Bausch Health Companies Inc.
Cara therapeutics, Inc.
Cipla Ltd.
Eilly Lilly and company
Evelo Biosciences
Galderma S.A.
LEO Pharma
MC2 therapeuitics
Recent Developments in the Market:
Global Pruritus Therapeutics Market Report Scope:
Historical Data: 2019-2020-2021
Base Year for Estimation: 2021
Forecast period: 2022-2029
Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered: Drug Type, Disease Type, Distribution Channel, Region
Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Drug Type
Corticosteroids
Antihistamines
Local Anesthetics
Immunosuppressant
Others
By Disease Type
Atopic Dermatitis
Allergic Contact Dermatitis
Urticaria
Others
By Distribution Channel
Hospital Pharmacies
Drug stores & Retail Pharmacies
Online providers
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World
List of tables and figures and dummy in nature, final lists may vary in the final deliverable
List of figures
List of tables and figures and dummy in nature, final lists may vary in the final deliverable